Beyond their accuracy, the second-generation Tau tracers have been produced to present more favorable pharmacokinetic properties and a more favorable dynamic range, including a higher affinity to neurofibrillary tangles, which should improve tauopathy assessment. The gene discussed is MAPT; the disease is tauopathy.